/ Home / Product Center / Advance Intermediates / Anti-Cancer /

Vismodegib Intermediate

2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide
CAS
879085-55-9
MF
C19H14Cl2N2O3S
MW
421.3
Purity
98%
Indication
Vismodegib Intermediate
Description

In January 2012, the US FDA approved vismodegib (also referred to as GDC-0449) for the treatment of adults with metastatic basal cell carcinoma (BCC),